PBM Says INNs Never Denoted Sameness, Calls For Shared Biosimilar Names

A pharmacy benefit manager associated with Blue Cross and Blue Shield plans has weighed in on the side of the generic drug industry in calling for shared names for biosimilars and originator products. Prime Therapeutics says International Nonproprietary Names have never signaled to healthcare professionals that products are the same and inappropriate substitution would be prevented by other means, such as state formularies. Prime, a PBM owned by 13 Blue Cross and Blue Shield health plans, counters several arguments made...